Other non-V600 mutations and BRAF fusions are found in about 4–14% of primary cutaneous melanoma cases [7], yet since they are part of the BRAF class II and III mutations they generally respond poorly to combined BRAF and MEK inhibition [7,8]. This evidence concerns the gene BRAF and cutaneous melanoma.